Work

Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real- world database (352)

Year: 2022

Type: article

Study design: Observational Study

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(22)01574-8

Authors: Jinan Liu, Premal Thaker, Jinlin Song, Linda Kalilani, Helen Guo, Eric Wu, Jean Hurteau, John Chan

Institutions: GlaxoSmithKline (United Kingdom), Washington University in St. Louis, Analysis Group (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4295225889

FWCI: 0.091

Cites:

Cited by: 1

Related to: 10